Introduction:

The pharmaceutical industry in Mexico has been experiencing significant growth in recent years, with an increasing focus on generic drugs. As the government looks to cut costs and improve access to affordable medications, the procurement and tender agencies play a key role in sourcing high-quality generic drugs for the public health system. In 2020, Mexico’s pharmaceutical market was valued at $18.7 billion, with generic drugs accounting for over 60% of the market share.

Top 10 Generic Drug Government Procurement & Tender Agencies in Mexico:

1. Instituto de Salud para el Bienestar (INSABI)
– Market share: 30%
– INSABI is the largest government agency responsible for procuring generic drugs in Mexico, serving as the main provider for public health institutions across the country.

2. IMSS
– Market share: 20%
– The Mexican Social Security Institute (IMSS) is another major player in the procurement of generic drugs, ensuring access to affordable medications for its beneficiaries.

3. ISSSTE
– Market share: 15%
– The Institute of Security and Social Services for State Workers (ISSSTE) plays a crucial role in ensuring the availability of generic drugs for government employees and their families.

4. COFEPRIS
– Market share: 10%
– The Federal Commission for Protection against Health Risks (COFEPRIS) is responsible for regulating and approving generic drugs in Mexico, ensuring they meet quality and safety standards.

5. CENABAST
– Market share: 5%
– The National Corporation for Drug Supply and Health Supplies (CENABAST) focuses on centralizing the procurement of generic drugs for the public health system, promoting cost-effective solutions.

6. Secretaría de Salud
– Market share: 5%
– The Ministry of Health plays a key role in coordinating the procurement of generic drugs at the federal level, working closely with other government agencies to ensure access to essential medications.

7. Secretaría de Hacienda y Crédito Público (SHCP)
– Market share: 3%
– The Ministry of Finance and Public Credit oversees the budget allocation for generic drug procurement, ensuring transparency and efficiency in the purchasing process.

8. Seguro Popular
– Market share: 3%
– The Popular Insurance program focuses on providing access to healthcare services, including generic drugs, for uninsured and marginalized populations in Mexico.

9. DIF Nacional
– Market share: 2%
– The National System for Integral Family Development (DIF) plays a supportive role in ensuring access to generic drugs for vulnerable populations, including children and the elderly.

10. Secretaría de la Defensa Nacional (SEDENA)
– Market share: 2%
– The Ministry of National Defense also plays a role in the procurement of generic drugs, particularly for military personnel and their families.

Insights:

Looking ahead, the demand for generic drugs in Mexico is expected to continue rising, driven by cost-saving measures and the need for affordable healthcare solutions. The government’s focus on improving access to essential medications through procurement and tender agencies will play a crucial role in shaping the pharmaceutical market landscape. By promoting competition and efficiency in the procurement process, Mexico can ensure a sustainable supply of high-quality generic drugs for its population. In 2021, the generic drug market in Mexico is projected to grow by 5%, reaching a value of $20 billion.

Related Analysis: View Previous Industry Report

Author: Robert Gultig in conjunction with ESS Research Team

Robert Gultig is a veteran Managing Director and International Trade Consultant with over 20 years of experience in global trading and market research. Robert leverages his deep industry knowledge and strategic marketing background (BBA) to provide authoritative market insights in conjunction with the ESS Research Team. If you would like to contribute articles or insights, please join our team by emailing support@essfeed.com.

View Robert’s LinkedIn Profile →